drugset / Trial / NCT06276868
Darsilide Combined With AI, Trastuzumab and Patuzumab in the Neoadjuvant Treatment of HR+/HER2+ Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
This study is intended to carry out a single arm, prospective, open clinical study, and use Darsilide combined with endocrine therapy, Trastuzumab and Patuzumab to treat early or locally advanced breast cancer of TPBC before surgery. It is intended to further explore the efficacy and safety of the new adjuvant treatment for TPBC patients with step-down therapy.
Timeline
- Start
- 2024-01-20
- Primary completion
- 2025-07-01
- Completion
- 2029-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dalcilib | Unknown | 150 mg | — |
| Subject | Letrozole | Other / unclassified | 2.5 mg | — |
| Subject | Pertuzumab | Monoclonal antibody | 420 mg/kg | Intravenous |
| Subject | Pertuzumab | Monoclonal antibody | 600 mg | Intravenous |
| Subject | Trastuzumab | Monoclonal antibody | 6 mg/kg | Intravenous |
| Subject | Trastuzumab | Monoclonal antibody | 600 mg | Intravenous |